The Effect of Levothyroxine Therapy on Bone Mineral Density: A Systematic Review of the Literature

R. Schneider; C. Reiners

doi:10.1055/s-2003-44704

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Exp Clin Endocrinol Diabetes 2003; 111(8): 455-470
DOI: 10.1055/s-2003-44704

Review

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

The Effect of Levothyroxine Therapy on Bone Mineral Density: A Systematic Review of the Literature

R. Schneider¹ , C. Reiners¹

¹Clinic for Nuclear Medicine, University of Würzburg, Würzburg, Germany

Further Information

Publication History

Received: January 29, 2003 First decision: April 14, 2003

Accepted: June 4, 2003

Publication Date:
09 January 2004 (online)

Also available at

Abstract
Full Text
References

Buy Article Permissions and Reprints

Abstract

Background

Currently debate still exists about the effects of thyroid hormone therapy on skeletal integrity, that is the safety of levothyroxine use with respect to bone mineral density.

Objective

A systematic review of the effects of TSH-suppressive and replacement levothyroxine therapy on bone mineral density evaluated main causes of conflicting results and its implications for clinical practice, and suggested directions of future research.

Data Source and Study Selection

A MEDLINE search identified English-language studies assessing bone mineral density under levothyroxine therapy published from 1990 to 2001.

Data Extraction

The studies were grouped by design and type of intervention. Outcomes were qualitatively analysed. Subgroup analysis assessed heterogeneity between studies.

Data Synthesis

Of 63 identified studies, 31 studies reported no effects of levothyroxine on bone mineral density, 23 studies showed partial beneficial or adverse, and 9 studies overall adverse effects. A significant dose-response was not found. There was a tendency towards peripheral cortical bone loss, suggesting a site-specific effect. In adolescents, men, and premenopausal women evidence for levothyroxine influence was weaker than in postmenopausal women. However, also findings in postmenopausal women remained unclear. The extent and etiology of underlying thyroid diseases also contributed to inconsistent results. Further, controversial results were due to substantial heterogeneity of studies. Above all, studies were limited by moderate quality, small size, and inadequate control for confounders.

Conclusions

Based on current studies there is insufficient evidence about effectiveness of levothyroxine on bone mineral density. All conclusions, however, must take into account the important methodical drawbacks. Present data may only be proved by longitudinal, high quality studies in homogeneous patients with sufficient sample size, clinical implication of future research remains questionable, though.

Key words

Levothyroxine therapy - bone mineral density

References

1 Abugassa S, Nordenström J, Eriksson S, Sjöden G. Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 1993; 76 1617-1621

Crossref PubMed Search in Google Scholar
2 Adlin E V, Maurer A H, Marks A D, Channick B J. Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med. 1991; 90 360-366

PubMed Search in Google Scholar
3 Affinito P, Sorrentino C, Farace M J, di Carlo C, Moccia G, Canciello P, Palomba S, Nappi C. Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. Acta Obstet Gynecol Scand. 1996; 75 843-848

PubMed Search in Google Scholar
4 Allain T J, McGregor A M. Thyroid hormones and bone. J Clin Endo. 1993; 139 9-18

PubMed Search in Google Scholar
5 Arafah B M. Increased need for thyroxine in women with hypothyroidism during estrogen therapy:. N Engl J Med. 2001; 344 1743-1749

Crossref PubMed Search in Google Scholar
6 Bauer D C, Nevitt M C, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: A prospective study. J Clin Endocrinol Meta. 1997; 82 2931-2936

PubMed Search in Google Scholar
7 Campos-Pastor M M, Munoz-Torres M, Escobar-Jimenez F, de Almodovar M R, Gimeno E J. Bone mass in females with different thyroid disorders: influence of postmenopausal status. Bone and Mineral. 1993; 21 1-8

PubMed Search in Google Scholar
8 Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001; 357 373-380

Crossref PubMed Search in Google Scholar
9 Cummings S R, Bates D, Black D M. Clinical use of bone densitometry. JAMA. 2002; 288 1889-1897

Crossref PubMed Search in Google Scholar
10 Demeester-Mirkine N, Bergmann P, Body J-J, Corvilain J. Calcitonin and bone mass status in congenital hypothyroidism. Calcif Tissue Int. 1990; 46 222-226

PubMed Search in Google Scholar
11 De Rosa G, Testa A, Maussier L, Calla C, Astazi P, Albanese C. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. Horm Metab Res. 1995; 27 503-507

PubMed Search in Google Scholar
12 De Rosa G, Testa A, Giacomini D, Carrozza C, Astazi P, Caradonna P. Prospective study of bone loss in pre- and postmenopausal women on L-thyroxine therapy for non-toxic goitre. Clin Endocrinol (Oxf). 1997; 47 529-535

Crossref PubMed Search in Google Scholar
13 Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine signifcantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrin Metab. 1991; 72 1184-1188

PubMed Search in Google Scholar
14 Duncan W E, Chang A, Solomon B, Wartofsky L. Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone. Thyroid. 1994; 4 183-190

PubMed Search in Google Scholar
15 Faber J, Galloe A M. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994; 130 350-356

PubMed Search in Google Scholar
16 Florkowski C M, Brownlie B E, Elliot J R, Ayling E M, Turner J G. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J. 1993; 106 443-444

PubMed Search in Google Scholar
17 Fowler P B, McIvor J, Sykes L, Macrae K D. The effect of long-term thyroxine on bone mineral density and serum cholesterol. J R Coll Physicians Lond. 1996; 30 527-532

PubMed Search in Google Scholar
18 Franklyn J A, Betteridge J, Daykin J, Holder R, Oates G D, Parle J V, Lilley J, Heath D A, Sheppard M C. Long-term thyroxine treatment and bone mineral density. Lancet. 1992; 340 9-13

Crossref PubMed Search in Google Scholar
19 Franklyn J A, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol (Oxf). 1994; 41 425-432

PubMed Search in Google Scholar
20 Franklyn J A, Betteridge J, Holder R, Sheppard M C. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a history of thyrotoxicosis. Thyroid. 1995; 5 359-363

PubMed Search in Google Scholar
21 Frusciante V, Carnevale V, Scillitani A, Zingrillo M, Dicembrino F, Giannatempo G M, Ghiggi M R, Minisola S. Global skeletal uptake of technetium-99 m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer. Eur J Nucl Med. 1998; 25 139-143

Crossref PubMed Search in Google Scholar
22 Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa Tsuruta K ;M, Nagayama Y, Villadolid M C, Yokoyama N, Nagataki S. Suppressive doses of thyroxine do not accelerate age-related bone loss in postmenopausal women. Thyroid. 1995 a; 5 13-17

PubMed Search in Google Scholar
23 Fujiyama K, Kiriyama T, Ito M, Nakata K, Yamashita H, Yokoyama N, Nagataki S. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. J Clin Endocrinol Metab. 1995 b; 80 2135-2138

Crossref PubMed Search in Google Scholar
24 Gam A N, Jensen G F, Hasselstrom K, Olsen M, Nielsen K S. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH. J Endocrinol Invest. 1991; 14 451-455

PubMed Search in Google Scholar
25 Garton M, Reid I, Loveridge N, Robins S, Murchinson L, Beckett G, Reid D. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol (Oxf). 1994; 41 747-755

PubMed Search in Google Scholar
26 Giannini S, Nobile M, Sartori L, Binotto Ciuffreda P ;M, Gemo G, Pelizzo Mr, D'Angelo A, Crepaldi G. Bone mineral density and metabolism in thyroidectomized patients treated with long-term L-thyroxine. Clin Sci (Colch). 1994; 87 593-597

PubMed Search in Google Scholar
27 Görres G, Kaim A, Otte A, Götze M, Müller-Brand J. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated carcinoma. Eur J Nucl Med. 1996; 23 690-692

PubMed Search in Google Scholar
28 Görres G, Theiler R, Müller-Brand J. Interfemur variation of bone density in patients receiving high-dose thyroxine therapy. Calcif Tissue Int. 1998; 63 98-101

Crossref PubMed Search in Google Scholar
29 Gonzales D C, Mautalen C A, Correa P H, el Tamer E, el Tamer S. Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol (Copenh). 1991; 124 521-525

PubMed Search in Google Scholar
30 Grant D J, McMurdo M E, Mole P A, Paterson C R, Davies R R. Suppressed TSH levels secondary to replacement therapy are not associated with osteoporosis. Clin Endocrinol (Oxf). 1993; 39 529-533

PubMed Search in Google Scholar
31 Greenspan S L, Greenspan F S, Resnick N M, Block J E, Friedlander A L, Genant H K. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med. 1991; 91 5-14

Crossref PubMed Search in Google Scholar
32 Greenspan S L, Greenspan F S. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999; 130 750-758

PubMed Search in Google Scholar
33 Grimes D A, Schulz K F. An overview of clinical research: the lay of the land. Lancet. 2002; 359 57-61

Crossref PubMed Search in Google Scholar
34 Guo C Y, Weetman A P, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol. 1997; 46 301-307

Crossref PubMed Search in Google Scholar
35 Hadji P, Hars O, Sturm G, Bauer T, Emons G, Schulz K D. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol. 2000; 142 445-450

Crossref PubMed Search in Google Scholar
36 Hanna F W, Pettit R J, Ammari F, Evans W D, Sandeman D, Lazarus J H. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxf). 1998; 48 229-234

PubMed Search in Google Scholar
37 Hawkins F, Rigopoulou D, Papapietro K, Lopez M B. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int. 1994; 54 16-19

Crossref PubMed Search in Google Scholar
38 Jodar E, Begona Lopez M, Garcia L, Rigoloulou D, Martinez G, Hawkins F. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int. 1998; 8 311-316

Crossref PubMed Search in Google Scholar
39 Jodar E, Martinez-Diaz-Guerra G, Azriel S, Hawkins F. Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease. Calcif Tissue Int. 2001; 69 84-87

Crossref PubMed Search in Google Scholar
40 Kann P, Jocham A, Beyer J. Hypothyreose, Hyperthyreose und Therapie mit Schilddrüsenhormonen: Einflüsse auf das Skelettsystem. Dtsch med Wschr. 1997; 122 1392-1397

PubMed Search in Google Scholar
41 Knudsen N, Faber J, Sierbaek-Nielsen A, Vadstrup S, Sörenson H A, Hegedüs L. Thyroid hormone replacement aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women. J Intern Med. 1998; 243 149-154

Crossref PubMed Search in Google Scholar
42 Kung A WC, Pun K K. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA. 1991; 265 2688-2691

Crossref PubMed Search in Google Scholar
43 Kung A W, Lorentz T, Tam S C. Thyroxine suppressive therapy decreases bone mineral density in postmenopausal women. Clin Endocrinol (Oxf). 1993; 39 535-540

PubMed Search in Google Scholar
44 Kung A WC, Yeung S SC. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: The effect of calcium and calcitonin. J Clin Endocrinol Metab. 1996; 81 1232-1236

Crossref PubMed Search in Google Scholar
45 Lauwers A, Alexandre C. Impact of thyroid hormone therapy. Rev Rhum. 1997; 64 112-119

PubMed Search in Google Scholar
46 Langdahl B L, Loft A GR, Eriksen E F, Mosekilde L, Charles P. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. Eur J Endocrinol. 1996; 134 702-709

Crossref PubMed Search in Google Scholar
47 Lecomte P, Lecureuil N, Osorio-Salazar C, Lecureuil M, Valat C. Effects of suppressive doses of levothyroxine treatment on sex-binding globulin and bone metabolism. Thyroid. 1995; 5 19-23

PubMed Search in Google Scholar
48 Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopenia in postmenopausal women. Clin Endocrinol (Oxf). 1992; 36 511-551

PubMed Search in Google Scholar
49 Marcocci C, Golia F, Bruno-Bossio G, Vignali E. Carefully monitored levothyroxine therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab. 1994; 78 818-823

Crossref PubMed Search in Google Scholar
50 Marcocci C, Golia F, Vignali E, Pinchero A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res. 1997; 12 72-77

PubMed Search in Google Scholar
51 McDermott M T, Perloff J J, Kidd G S. A longitudinal assessment of bone loss in women with levothyroxine-suppressive benign thyroid disease and thyroid cancer. Calcif Tissue Int. 1995; 56 521-525

Crossref PubMed Search in Google Scholar
52 Mirzaei S, Krotla G, Knoll P, Korsika K, Köhn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Acta Med Austriatica. 1999; 26 29-31

PubMed Search in Google Scholar
53 Müller C G, Bayley T A, Harrison J E, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid. 1995; 5 81-87

PubMed Search in Google Scholar
54 Nuzzo V, Lupoldi G, Esposito Del Puente A, Rampone E, Carpinelli A, Del Puente A E, Oriente P. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. Gynecol Endocrinol. 1998; 12 333-337

PubMed Search in Google Scholar
55 Ongphiphadhanakul B, Puavilai G, Rajatanavin R. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women. J Med Assoc Thai. 1996; 79 563-567

PubMed Search in Google Scholar
56 Oxman A D. Checklist for review articles. BMJ. 1994; 309 648-651

Crossref PubMed Search in Google Scholar
57 Pines A, Dotan I, Tabori U, Villa Y, Mijatovic V, Levo Y, Ayalon D. L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism. Gynecol Endocrinol. 1999; 13 196-201

PubMed Search in Google Scholar
58 Pioli G, Pedrazzoni M, Palummeri E, Sianesi M, Del Frate R, Vescovi P P, Prisco M, Ulietti V, Costi D, Passeri M. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh). 1992; 126 238-242

PubMed Search in Google Scholar
59 Quan M L, Pasieka J L, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol. 2002; 79 62-70

Crossref PubMed Search in Google Scholar
60 Radetti G, Castellan C, Tato L, Platter K, Gentili L, Adami S. Bone mineral density in children and adolescent females treated with high doses of L-thyroxine. Horm Res. 1993; 39 127-131

PubMed Search in Google Scholar
61 Ribot C, Tremollieres F, Pouilles J M, Louvet J P. Bone mineral density and thyroid hormone therapy. Clin Endocrinol (Oxf). 1990; 33 143-153

PubMed Search in Google Scholar
62 Rosen H N, Moses A C, Garber J, Ross D S, Lee S L, Ferguson L, Chen V, Lee K, Greenspan S L. Randomized trial of pamidronate in patients with thyroid cancer: Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab. 1998; 83 2324-2330

Crossref PubMed Search in Google Scholar
63 Ross D S. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with hypothyroidism: a randomized, prospective study. Am J Med. 1993; 95 385-388

Crossref PubMed Search in Google Scholar
64 Ross D S. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid. 1994; 4 319-326

PubMed Search in Google Scholar
65 Saggese G, Bertelloni S, Baroncelli G I, Costa S, Ceccarelli C. Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study. Eur J Pediatr. 1996; 155 452-457

PubMed Search in Google Scholar
66 Schneider P, Berger P, Kruse K, Börner W. Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients. J Endocrinol Invest. 1991; 14 934-942

PubMed Search in Google Scholar
67 Schneider D L, Barrett-Connor E L, Morton D J. Thyroid hormone use and bone mineral density in elderly women. JAMA. 1994; 271 1245-1249

Crossref PubMed Search in Google Scholar
68 Schneider D L, Barrett-Connor E L, Morton D J. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med. 1995; 155 2005-2007

Crossref PubMed Search in Google Scholar
69 Singh N, Singh P N, Hershman J M. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000; 283 2822-2825

Crossref PubMed Search in Google Scholar
70 Siris E S, Miller P D, Barrett-Connor E, Faulkner K G, Wehren L E, Abbott T A, Berger M L, Santora A C, Sherwood L M. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA. 2001; 22 2815-2822

PubMed Search in Google Scholar
71 Stall G M, Harris S, Sokoll L J, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med. 1990; 113 265-269

PubMed Search in Google Scholar
72 Stefan J J, Limanova Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner. 1992; 17 377-388

Crossref PubMed Search in Google Scholar
73 Taelman P, Kaufman J M, Janssens X, Vandecauter H, Vermeulen A. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone. Clin Endocrinol (Oxf). 1990; 33 107-117

PubMed Search in Google Scholar
74 Toh S H, Brown P H. Bone mineral content in hypothyroid male patients with hormone replacement: A 3-year study. J Bone Miner Res. 1990; 5 463-467

PubMed Search in Google Scholar
75 Toivonen J, Tahtela R, Laitinen K, Ristele J, Valimaki M J. Markers of bone turnover in patients with differentiated thyroid cancer and following withdrawal of thyroxine therapy. Eur J Endocrinol. 1998; 138 667-673

Crossref PubMed Search in Google Scholar
76 Tümer L, Hasanoglu A, Cinaz P, Aysun B. Bone mineral density and metabolism in children treated with L-thyroxine. J Pediatr Endocrinol Metab. 1999; 12 519-523

PubMed Search in Google Scholar
77 Uzzan B, Campos J, Cucherat M, Nony P, Boissel J P, Perret G Y. Effects on bone mass of long-term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab. 1996; 81 4278-4289

Crossref PubMed Search in Google Scholar
78 Williams J B. Adverse effects of thyroid hormones. Drugs Aging. 1997; 11 460-469

PubMed Search in Google Scholar
79 Wüster C, Raue F, Meyer C, Bergmann M, Ziegler R. Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. J Endocrinol. 1992; 134 141-147

PubMed Search in Google Scholar

Dr. Rita Schneider

Clinic for Nuclear Medicine

Josef-Schneider-Straße 2

97080 Würzburg

Germany

Phone: + 4993120135096

Fax: + 49 9 31 20 13 52 47

Email: schneider_r1@nuklearmedizin.uni-wuerzburg.de